Category: Risalto
PHSE joins Nuclear Medicine Europe
Ocotober 22, Milan – PHSE joins Nuclear Medicine Europe, the Industrial Association representing the leading pharmaceutical and imaging equipment companies in the field of nuclear medicine throughout Europe. Today’s handshake at EANM 2024 Congress between Martinus Blauwhoff, President of Nuclear Medicine Europe, and Paul Rice, Chief Development Officer of PHSE International, kicks off the valuable partnership.
“We have identified the Nuclear Medicine Europe Association as an opportunity to engage with industry experts, ranging from pharmaceutical companies to reactor operators worldwide, which we see as an essential part of our continuous improvement in offering highly specialised global transport services for the radiopharmaceutical market. Our first-hand involvement in working groups on topics of mutual interest, ranging from Security Of Supply, Therapy, Regulatory Affairs & Quality, and the Transport, will hopefully help bring real value to the complex radiopharmaceutical supply chain. While in the past drug distribution was considered the last chain in the manufacturing process, we strongly believe that logistics is increasingly a key asset and critical success factor in meeting the association’s challenges of Innovation, Healthcare For Everyone and Patient Safety within the sector. The three fundamental pillars that drive our daily actions as well”, said Paul Rice.
PHSE also lands in Germany with the acquisition of Moving Forward International
Milan, 2 October 2024 – PHSE, a leading group in temperature-controlled, and time critical pharmaceutical logistics, announces that it has completed the acquisition of 100% of Moving Forward International GmbH (MFI), a German freight forwarding company active in the international shipment (import and export from Germany) of pharmaceuticals, with a strong specialisation in the transport of radiopharmaceuticals, the new frontier in cancer therapies.
The transaction confirms the PHSE Group’s focus on the Radio Pharma market in order to meet the growing demand from large pharmaceutical companies for highly specialised global transport services capable of guaranteeing the delivery of products with a very short shelf-life (even within 24/48 hours) to the patient. The acquisition also provides the Group with entry into a new and strategic key market, Germany, Europe’s leading pharmaceutical market.
“We are excited to welcome Moving Forward International to our Group. MFI’s assets and expertise in radiopharmaceuticals further expand our GDP-compliant and IATA-certified European network for healthcare distribution by land and air worldwide. They will also accelerate our positive growth in Radio Pharma distribution, in which PHSE is one of the pioneers, having started operations in this specialist segment over a decade ago. Today, as well as our own increasing footprint and more than 70 specialist vehicles (15% of the PHSE fleet), we have an extensive global network of qualified agents which enables us to deliver both international and domestic solutions to our customers. We will further expand our own footprint in the coming years, to meet the growing needs of the market”, said Eddy De Vita, Executive Chairman of PHSE Group.
CEO Dario Guerrera and his expert team, will continue to lead the MFI business, which has its operational headquarters and warehousing at Frankfurt Airport, Europe’s first cargo hub, and will be supported by the broader PHSE Group capabilities.
“I am excited and proud to join the PHSE family, and to be able to bring even more capability and experience to support our customers”, commented Dario Guerra, CEO of MFI.
The PHSE Group expects to end 2024 with consolidated revenues of more than 100 million euros.
The transaction was concluded with the financial support of SIMEST, which positively assessed PHSE’s international development strategy and, in particular, the acquisition of MFI.
Fabio Mioli is the new CEO of PHSE International
Fabio Mioli joins the PHSE Group today. As of 1 January 2025, he will assume the role of head of PHSE International, the Group’s sub-holding in which all foreign activities are concentrated, reporting directly to Eddy De Vita, Executive President of PHSE Group. Fabio Mioli assumes this responsibility from Graham Inglis, who has reorganised and developed the Group’s International business since 2020, and who will continue to lead this business until 31 December 2024, thus enabling an organized transition.
Fabio Mioli brings to the Group a wealth of experience in the Life Sciences Healthcare sector, having occupied senior roles in the commercial, strategic, purchasing, operations and supply chain areas for both pharmaceutical companies (Wyeth Pharmaceuticals, Schering-Plough and Procter Gamble) and service companies (such as Alliance Boots, DHL Supply Chain and UPS Healthcare, where he held the positions of Commercial Affairs Dir. GM, BU Director of Hospital, Specialty Pharma, Medical Devices and Country Manager Healthcare South Europe).
“Fabio’s appointment represents an exciting development for PHSE International. In this new position, he will be responsible for driving our growth in Europe, America and Asia, both organically and through strategic acquisitions. This is work already started by Graham Inglis, whom I would very much like to thank”, commented Eddy De Vita, Executive President of the company.
Since joining the business, Graham Inglis has contributed to the Group’s overall development, as well as growing the foreign business and delivering important results for PHSE International. Achievements include the rationalisation of the UK, US and Singapore branches, the opening of the Spanish hub, the three acquisitions in the UK, India and Brazil; and, further acquisitions, already at an advanced stage of development, are likely to follow in the coming months. Graham Inglis will remain as a member of the Board of Directors of PHSE, and will continue to support the strategic development of the Group.
The turnover of the Group, one of the world’s leading players in temperature-controlled Healthcare transport and last-mile distribution, has more than tripled in four years, rising from around € 27 million in 2019 to around € 86 million in 2023 (cagr +33%) also thanks to the completion of five acquisitions, three of which abroad (UK, India and Brazil) and two in Italy. These acquisitions have supported the development of new services for customers, including direct-to-patient, ground and air transport of radiopharmaceuticals and cell gene therapies, and strengthened the Group’s international capabilities.
Hospital Patient Care Event. Register now!
Innovation and sustainability challenges are pushing us to find new solutions to be closer to our patients.
But how is it possible to bring the place of care closer and closer to people? How will the healthcare industry and supplychain have to organize themselves? What are the next challenges to overcome?
This event, organized by PHSE and PHD Life Science, in collaboration with Humanitas Research Hospital and with the media partnership of EDRA – FARMACISTA33, will be a common moment where we can explore the hospital of the future and recognize what will be these next challenges between innovation, research, sustainability and patientcenteredness, from a multidisciplinary perspective.
During the event, hosted by Sky Tg24 journalist Tonia Cartolano, important speakers will share their thoughts on current trends, projects and applications:
- Matteo Giovanni Della Porta, Head, Leukemia Unit – Cancer Center, Humanitas Research Hospital Full Professor of Hematology, Humanitas University
- Damiano Greco, Logistics Operations Country Lead, MSD
- Marcello Pani, Director UOC Hospital Pharmacy, Policlinico Universitario A. Gemelli IRCCS Roma
- Pierluigi Petrone, Presidentt Assoram e Vice President Farmindustria
- Beatrice Salvatori, Scientist Project Manager, Negedia
- Victor Savevski, Chief Innovation Officer e AI Center Director, Humanitas
- Marco Gorini, Project Head Digital Health Innovation, Astrazeneca
- Danilo De Spirito, Market Innovation Access Head, Bayer
- Annalisa Scopinaro, President UNIAMO, Federazione Italiana Malattie Rare
- Tiziana Mele, Managing Director, Lundbeck
Register now now:
https://lnkd.in/dZST6bCTFor more information and to discover the program, visit:
https://lnkd.in/dZST6bCT
PHSE digitizes quality with
e-QMS
PHSE is the first healthcare transport company in Italy to use e-QMS (Electronic Quality Management System), which is structured to standardize and speed up activities that were previously handled on paper.
Since March 2024, the implementation of the system, available to all trained and authorized employees, has helped to digitize and streamline numerous processes: management of document flows, non-conformity, corrective actions and preventive actions (CAPA). The aim, in the long term, is to progressively integrate subsequent modules and extend it globally.
The system, which meets the stringent requirements of the pharmaceutical industry, is validated by Adeodata in accordance with ISPE guideline GAMP 5 and FDA CFR 21 Part 11.
The move to digital data management and quality processes follows the recent nationwide implementation of radio frequency identification (RFID) traceability of each individual package.
These investments take the Digital Transformation of the company’s IT and Quality Assurance areas a step further, bringing benefits in terms of quality, training, product safety and ensuring compliance with the strict regulations that govern the industry.
When Logistics saves lives
When Logistics saves lives and the collaboration is deep among Operations, Quality, HR, and Information Technology to ensure the highest quality in logistics flows all the way to final delivery to hospitals, laboratories, research centers, nursing homes, veterinarians and to patients’ homes.
Thank you Gaia Fiertler for listening, collecting, and reporting in the magazine “Logistica” the PHSE case and point of view of Paolo Gagliuardi La Gala and Mattia Scoglio on Logistics.
Have a nice reading!
New Transit Point in Italy for PHSE
PHSE, a leader in temperature-controlled transport of pharmaceuticals, biotech, clinical trials and biological samples serving the hospital channel, opens a new important distribution transit point in Vicenza, northeastern Italy. The new platform replaces the previous site in Padua and represents, above all, a new reference hub for last-mile distribution to hospitals, patients and laboratories in the Triveneto region.
The fully refrigerated platform of more than 1,000 square metres includes a +15/+25 °C warehouse, a +2/+8 °C pre-cold room, and a 50 square metres cold room for the management of goods requiring specialist cold chain solution. The platform utilizes state of the art monitoring technology that enables real-time visibility at all stages of the end-to-end supply chain, frominbound to delivery to hospitals and patients’ homes. “By taking advantage of its strategic positioning, close to the Milan-Venice highway, and the PHSE network’s RFID technology, the Vicenza branch will further improve the already optimal delivery lead times in the Triveneto region and, through RFID reading of inbound and outbound tags, the traceability of individual packages for greater accuracy, visibility, speed in product tracking and patient safety“, said Paolo Gagliardi La Gala, Head of Quality at PHSE.
These are all extremely valuable features and technologies for pharmaceutical industries, which require rigorous adherence to high standards of quality and safety along the entire distribution network.